Wang, Xia
Perry, Thomas A
Caroupapoullé, Jimmy
Forrester, Alexander
Arden, Nigel K
Hunter, David J
Funding for this research was provided by:
Merck Serono Pty
Article History
Received: 6 March 2021
Accepted: 26 May 2021
First Online: 18 June 2021
Declarations
:
: All participants provided written informed consent for participation in the study. The study was approved by the Human Research Ethics Committee of the University of Sydney (Reference no 2019/846).
: Not applicable.
: DJH provides consulting advice for Pfizer, Lilly, TLC bio and Merck Serono. NKA reports grants from Merck, personal fees from Merck, Flexion, Regeneron and Pfizer/Lilly outside the submitted work. All the other authors have no conflicts of interest to disclose. NKA has received honorariums from Novartis, Alliance for Better Health, and Lilly; held advisory board positions (which involved receipt of fees) at Merck, Merck Sharp and Dohme, Roche, Novartis, Smith and Nephew, Q-MED, Nicox, Servier, GlaxoSmithKline, Schering-Plough, Pfizer, and Rottapharm; and received consortium research grants from Alliance for Better Bone Health, Amgen, Novartis, Merck Sharp and Dohme, Servier, Eli Lilly, and GlaxoSmithKline; he has no other relationships or activities that could appear to have influenced the submitted work.